Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in adults in the UK. Ibrutinib, an oral Bruton tyrosine kinase inhibitor (BTKi) for CLL approved by the UK's National Institute for Health and Care Excellence in January 2017, represented a major shift in CLL management. Real‐worl...

Descripción completa

Detalles Bibliográficos
Autores principales: Hillmen, Peter, Xie, Jing, Yong, Alan S. M., Waweru, Catherine, Sorof, Thuy Anh, Goyal, Ravi K., Davis, Keith L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematologic Malignancy ‐ Lymphoid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175847/
https://www.ncbi.nlm.nih.gov/pubmed/35845284
http://dx.doi.org/10.1002/jha2.174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175847/
https://www.ncbi.nlm.nih.gov/pubmed/35845284
http://dx.doi.org/10.1002/jha2.174

Ejemplares similares